Pharma Mar (NASDAQ:PHMMF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday. The brokerage presently has a $5.00 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 13.12% from the stock’s current price.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Pharma Mar (PHMMF) opened at 4.42 on Thursday. Pharma Mar has a 52 week low of $2.22 and a 52 week high of $4.80. The company’s market capitalization is $1.10 billion. The company has a 50-day moving average of $4.48 and a 200-day moving average of $3.83.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2796912/zacks-investment-research-upgrades-pharma-mar-phmmf-to-buy.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.